Daisy Mugo
Kilifi, Kenya
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Determining the dose-response relationship for pneumococcal conjugate vaccines: a nested analysis of the fractional dose PCV trial.
Journal: Vaccine
Published: July 27, 2025
Comparative performance of the InBios SCoV-2 Detect TM IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populations.
Journal: Wellcome open research
Published: July 25, 2025
Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial.
Journal: Lancet (London, England)
Published: June 14, 2025
Low-Dose Yellow Fever Vaccine in Adults in Africa.
Journal: The New England journal of medicine
Published: February 19, 2025
Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.
Journal: Wellcome open research
Published: November 26, 2024
Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial.
Journal: The New England journal of medicine
Published: September 27, 2024
Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya.
Journal: BMC infectious diseases
Published: July 29, 2024
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Journal: Wellcome open research
Published: November 22, 2023
SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022.
Journal: Influenza and other respiratory viruses
Published: April 05, 2023
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
Journal: The Lancet. Infectious diseases
Published: January 05, 2023
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Journal: The Lancet. Infectious diseases
Published: November 07, 2022
Last Updated: 09/26/2026